Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireProductiveAssets.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Maturities of marketable securities | 108,363 | 60,672 |
| Purchases of marketable securities | (65,837) | (59,225) |
| Purchases of property and equipment | — | (20) |
| Net cash provided by investing activities | 42,526 | 1,427 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options | 10,053 | 234 |
| Net cash provided by financing activities | 10,053 | 234 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's capex?
- Enliven Therapeutics (ELVN) reported capex of $0 in Q1 2026.
- How has Enliven Therapeutics's capex changed year-over-year?
- Enliven Therapeutics's capex decreased by 100.0% year-over-year, from $20K to $0.
- What is the long-term trend for Enliven Therapeutics's capex?
- Over 2 years (2022 to 2024), Enliven Therapeutics's capex has grown at a -73.2% compound annual growth rate (CAGR), from $612K to $44K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Enliven Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude